CoChat

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

Open access

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Background Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study.Methods Eligible patients were women aged 18 years or older with HER2-positive, histologically confirmed primary invasive breast adenocarcinoma, no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left-ventricular ejection fraction of 55% or more before the first dose of trastuzumab. Radiotherapy or hormone therapy was allowed. Patients were randomised (randomly permuted blocks of four) to receive four cycles of 600 mg fixed-dose subcutaneous adjuvant trastuzumab via a single-use injection device or hand-held syringe followed by four cycles of standard intravenous trastuzumab, or the reverse sequence. Randomisation was stratified by de-novo versus non-de-novo use of intravenous trastuzumab. The primary endpoint was the proportion of patients indicating an overall preference for subcutaneous or intravenous trastuzumab, assessed by patient interview in the evaluable intention-to-treat (ITT) population (patients who completed both interviews and had at least one administration of both subcutaneous and intravenous trastuzumab). Data collection for PrefHer is ongoing. This study is registered with ClinicalTrials.gov, number NCT01401166.Findings 124 patients were randomly allocated to receive subcutaneous followed by intravenous trastuzumab, and 124 to receive the reverse sequence. 117 patients in the subcutaneous first group and 119 in the intravenous first group were included in the evaluable ITT population. Subcutaneous trastuzumab via the single-use injection device was preferred by 216 patients (91·5%, 95% CI 87·2-94·7; p<0·0001). Only 16 patients preferred intravenous trastuzumab (6·8%, 3·9-10·8), and four had no preference (1·7%, 0·5-4·3). Clinician-reported adverse events occurred in 141 of 242 (58%) patients during the pooled subcutaneous periods and 105 of 241 (44%) patients during the pooled intravenous periods; seven (3%) and five (2%) were grade 3, no patients had a grade 4 or 5 event. The most common grade 3 adverse event was influenza (two [0·8%] patients).Interpretation Patient preference and safety results from PrefHer, combined with the known non-inferior efficacy and pharmacokinetic and safety profile data, suggest that a fixed dose of 600 mg trastuzumab administered subcutaneously every 3 weeks is a validated, well tolerated treatment option for HER2-positive breast cancer, and is the preferred treatment of patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(13)70383-8

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. De Cock E, Semiglazov V, Lopez-Vivanco G, et al. Time savings with trastuzumab subcutaneous vs intravenous administration: a time and motion study. 13th St Gallen International Breast Cancer Conference 2013; St Gallen, Switzerland; March 13–16, 2013. Abstract 328.

Cited by

See all 246

Metadata

Authors
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., Scotto, N., Osborne, S., & Fallowfield, L.
Affiliations
  • Centre Hospitalier Universitaire de Besançon (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Velindre NHS Trust (GB)
  • Sunnybrook Health Science Centre (CA)
  • Copenhagen University Hospital (DK)
  • European Institute of Oncology (IT)
  • Hospital de Cruces (ES)
  • Brighton and Sussex Medical School (GB)
  • F. Hoffmann-La Roche AG (CH)
Corresponding author
Pivot, Xavier
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2013-09
Volume
14
Issue
10
Pages
962-970
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2024903800
Cited by
230
References
22
Citations by year
2026: 16 · 2025: 16 · 2024: 22 · 2023: 16 · 2022: 9 · 2021: 19 · 2020: 12 · 2019: 21 · 2018: 14 · 2017: 19 · 2016: 12 · 2015: 24 · 2014: 27 · 2013: 3
FWCI
11.77
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
trastuzumab, HER2-positive breast cancer, early breast cancer, subcutaneous administration, intravenous administration, patient preferences, adjuvant therapy, non-inferiority, fixed-dose dosing, patient-reported outcomes
MeSH terms
Trastuzumab, Adult, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Injections, Subcutaneous, Middle Aged, Cross-Over Studies, Erb-b2 Receptor Tyrosine Kinases, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. https://app.cochat.ai/papers/10.1016/s1470-2045(13)70383-8
The paper
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., Scotto, N., Osborne, S., & Fallowfield, L. (2013). Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(13)70383-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.